Targeting B-cell maturation antigen in multiple myeloma.
作者： Yu-Tzu Tai , Kenneth C Anderson
DOI: 10.2217/IMT.15.77
关键词:
摘要: Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), cell surface protein universally expressed on malignant plasma cells , has emerged as very selective to be targeted in novel treatments MM. We here first review BCMA-related biology, and then highlight the recent clinical development of afucosylated anti-BCMA monoclonal antibody conjugated monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric receptor-expressing T targeting BCMA may also induce specific durable anti-MM responses by patients' own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) currently ongoing relapsed refractory MM patients.
futuremedicine.com
sci-hub.se 参考文章(77)
Evren Alici, IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Current Opinion in Molecular Therapeutics. ,vol. 12, pp. 724- ,(2010)
Barbara Gatto, Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells Current opinion in investigational drugs. ,vol. 9, pp. 1216- 1227 ,(2008)
Kevin R. Kelly, Asher Chanan-Khan, Leonard T Heffner, George Somlo, David S. Siegel, Todd Zimmerman, Anand Karnad, Nikhil C. Munshi, Sundar Jagannath, Allen L. Greenberg, Sagar Lonial, Vivek Roy, Sikander Ailawadhi, Farima Barmaki-Rad, Shailesh Chavan, Pankaj Patel, Andrea Wartenberg-Demand, Thomas Haeder, Kenneth C Anderson, Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib Blood. ,vol. 124, pp. 4736- 4736 ,(2014) , 10.1182/BLOOD.V124.21.4736.4736
Jane A. Gross, Janet Johnston, Sherri Mudri, Rachel Enselman, Stacey R. Dillon, Karen Madden, Wenfeng Xu, Julia Parrish-Novak, Don Foster, Cathy Lofton-Day, Margaret Moore, Alisa Littau, Angelika Grossman, Harald Haugen, Kevin Foley, Hal Blumberg, Kim Harrison, Wayne Kindsvogel, Christopher H. Clegg, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature. ,vol. 404, pp. 995- 999 ,(2000) , 10.1038/35010115
Juan Flores-Montero, Ruth de Tute, Bruno Paiva, José Juan Perez, Sebastian Böttcher, Henk Wind, Luzalba Sanoja, Noemí Puig, Quentin Lecrevisse, María Belén Vidriales, Jacques J. M. van Dongen, Alberto Orfao, Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma Cytometry Part B-clinical Cytometry. ,vol. 90, pp. 61- 72 ,(2016) , 10.1002/CYTO.B.21265
Yu-Tzu Tai, Kenneth C. Anderson, Myeloma: Principles of pathway directed therapy ,(2013) , 10.1017/CBO9780511862465.009
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric, Mark Raffeld, Debbie-Ann N. Nathan, Brock J. Lanier, Richard A. Morgan, Steven A. Rosenberg, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood. ,vol. 116, pp. 4099- 4102 ,(2010) , 10.1182/BLOOD-2010-04-281931
Sagar Lonial, Risky business in myeloma Blood. ,vol. 114, pp. 496- 497 ,(2009) , 10.1182/BLOOD-2009-04-217281
Robert J. Lutz, Kathleen R. Whiteman, Antibody-maytansinoid conjugates for the treatment of myeloma mAbs. ,vol. 1, pp. 548- 551 ,(2009) , 10.4161/MABS.1.6.10029
Arthur L. Shaffer, N. C. Tolga Emre, Laurence Lamy, Vu N. Ngo, George Wright, Wenming Xiao, John Powell, Sandeep Dave, Xin Yu, Hong Zhao, Yuxin Zeng, Bangzheng Chen, Joshua Epstein, Louis M. Staudt, IRF4 addiction in multiple myeloma. Nature. ,vol. 454, pp. 226- 231 ,(2008) , 10.1038/NATURE07064